Stock AnalizSchrodinger, Inc. SDGR
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Schrodinger, Inc. (SDGR) is a healthcare company listed in the US with a market value of about $2.2B. In the twelve months to September 30, 2026 it had revenue of $269M and net income of -$59M, a net margin of -22.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 19% a year, a 5-year average ROIC of -24%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $269M | $256M | $208M | $217M | $181M | $138M | $108M | $86M |
| Net income | -$59M | -$103M | -$187M | $41M | -$149M | -$100M | -$24M | -$25M |
| Free cash flow | -$117M | $12M | -$165M | -$150M | -$128M | -$78M | $14M | -$28M |
| EPS (diluted) | $-0.79 | $-1.41 | $-2.57 | $0.54 | $-2.10 | $-1.42 | $-0.41 | $-4.09 |
| Net margin | -22.0% | -40.4% | -90.2% | 18.8% | -82.4% | -72.8% | -22.6% | -28.7% |
| ROIC | — | -27.9% | -30.7% | -24.9% | -20.5% | -13.8% | -7.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $33.57, 14% above the current price; targets range from $29.00 to $37.00; the consensus rating is “Buy”; expected EPS is $-1.52 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Schrodinger pay a dividend?
Not currently.
Is Schrodinger a good stock to buy?
We do not give buy or sell advice. Schrodinger scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.